Create an Adult Immunotherapy Network

NCI has announced several funding opportunities that align with the Cancer Moonshot.

See Funding Opportunities

Immunotherapy leverages the ability of the immune system to recognize and destroy infected, damaged, and transformed cells. This type of cancer treatment often enhances the activity of immune cells called ‘effector T cells’, whose function is to kill cancer cells by distinguishing them from their normal counterparts. However, barriers remain and need to be addressed to improve the effectiveness of immunotherapy.

While there has been some promising success in treating certain cancers with immunotherapy, it has been less effective in others. It is often more difficult to safely and effectively target the cancer cells in solid tumors without harming normal tissues. The tumor’s microenvironment may also suppress the immune system, limiting its ability to fight off the cancer.

This recommendation is focused on creating an adult cancer immunotherapy translational network to overcome these barriers and develop immunotherapies that are effective for a diverse group of patients with various cancer types. In addition, the network aims to create vaccines that will aid effector T cells in recognizing cancers in their premalignant stages, effectively preventing new cancer cases.

Ultimately, the hope is to develop new immunotherapies and improve the effectiveness of current immunotherapy treatments to reduce the burden of cancer in adults.

NCI has awarded funding to several research projects that align with the panel's recommendation to address immunotherapy in adults:

The Immuno-Oncology Translational Network (IOTN)

This collaborative network is working to accelerate the discovery of new immune targets for cancer treatments and development of new immunotherapies to treat and prevent adult cancers. The IOTN consortium includes researchers who are investigating immune mechanisms involved in cancer progression, evaluating new immunotherapies, and developing preventive cancer vaccines. The network also has a Cellular Immunotherapy Data Resource that supports a data registry that collects information about adult patients receiving cell-based immunotherapies, which can inform future studies of immunotherapies.

The IOTN Data Management and Resource Sharing Center promotes collaboration between IOTN investigators and outreach of the network to the cancer research community.

To learn more about the funding opportunities available and how to apply, view or download the IOTN Pre-Application Webinar slides.

NCI Center for Cell-Based Therapy (CCT)

NCI created an intramural cell-based therapy center that focuses on the use of living immune cells for cancer immunotherapies. The center supports the discovery and development of new cellular immunotherapies to treat cancer patients. The center is performing basic research of cell-based cancer therapies, accelerating translation of cell-based immunotherapy findings to the clinic, training scientists for immunotherapy studies, and providing cancer researchers with access to immunotherapy-related technologies.

Adult Immunotherapy Projects Awarded Cancer Moonshot Funding

Awarded Projects
Funding Opportunity Project Title Institution Principal Investigator(s)
Immuno-Oncology Translational Network (IOTN): Cancer Immunotherapy Research Projects (U01) Enhancing Cell Therapy for Brain Tumors Children's Research Institute Bollard, Catherine M; Cruz, Conrad Russell Young; Jones, Richard J; Savoldo, Barbara
B Cell-Dependent Anti-Tumor Immunity in Ovarian Cancer H. Lee Moffitt Cancer Center & Research Institute Conejo-Garcia, Jose R
N-Glycosylation and Immunotherapy for Cancer University of California - Irvine Demetriou, Michael
Immunosuppressive Mechanisms Responsible for Development of Non-Viral Liver Cancer and Control of its Response to Immune Checkpoint Inhibitors University of California - San Diego Karin, Michael; El-Khoueiry, Anthony Boutros; Tsukamoto, Hidekazu
Muc1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies Dana Farber Cancer Institute Kufe, Donald W; Wong, Kwok Kin
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies University of Wisconsin - Madison Morris, Zachary Scott; Weichert, Jamey P
Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck Cancers La Jolla Institute for Allergy & Immunology Schoenberger, Stephen Philip; Gutkind, J Silvio; Rao, Anjana
Targeting the Immunosuppressive Tumor Microenvironment to Enhance Efficacy of Radiotherapy and Immuno-radiotherapy for Oral Cancer Baylor College of Medicine Sikora, Andrew Gregory; Annapragada, Ananth V
Molecular and Immune Drivers of Immunotherapy Responsiveness in Prostate Cancer Dana Farber Cancer Institute Van Allen, Eliezer M; Fong, Lawrence
Targeting Alternative Splicing for TCR Discovery in Small Cell Carcinomas University of California - Los Angeles Witte, Owen N; Crooks, Gay M; Xing, Yi
Epithelium-derived Alarmins Role in Breast Cancer Immunoprevention Massachusetts General Hospital Demehri, Shadmehr
Neoantigen Vaccination for Lynch Syndrome Immunoprevention Weill Medical College of Cornell University Lipkin, Steven M; Vilar-Sanchez, Eduardo
Immuno-Oncology Translation Network (IOTN): Data Management and Resource-Sharing Center (DMRC) (U24) Immuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCI Roswell Park Cancer Institute Hutson, Alan David; Liu, Song; Morgan, Martin T; Odunsi, Kunle O
Immuno-Oncology Translation Network (IOTN): Cellular Immunotherapy Data Resource (CIDR) (U24) Immuno-Oncology Translation Network (IOTN): Cellular Immunotherapy Data Resource (CIDR) Medical College of Wisconsin Horowitz, Mary Maresca
Canine Immunotherapy Trials and Correlative Studies (U01) Canine Immuno Neurotherapeutics University of Alabama at Birmingham Chambers, M.R.
Enhancing the Efficacy of Immunotherapy in DLBCL using Rational Combination Approaches Tufts University London, Cheryl A; Richards, Kristy L
Novel Combined Immunotherapeutic Strategies for Glioma: Using Pet Dogs as a Large Animal Spontaneous Model University of Minnesota Pluhar, Grace Elizabeth
Enhancing Natural Killer Immunotherapy with First-in-Dog Trials of Inhaled Recombinant IL-15 and Super-agonist IL-15 in Naturally Occurring Canine Cancers University of California at Davis Canter, Robert; Rebhun, Robert
Optimizing Novel Immunotherapy Combinations Targeting the Tumor Microenvironment in Canine Spontaneous Osteosarcoma Colorado State University Dow, Steven W; London, Cheryl A
Coordinating Center for Canine Immunotherapy Trials and Correlative Studies (U24) Coordinating Center for Canine Immunotherapy Trials and Correlative Studies University of Pennsylvania Mason, Nicola J; Propert, Kathleen Jjoy
Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies on the Tumor Microenvironment (U01) Interrupting Cellular Crosstalk in the Immunosuppressive Microenvironment of Pancreas Cancer University of Michigan Crawford, Howard C; Pasca Di Magliano, Marina
Systematic Interrogation of the Pancreatic Cancer Microenvironment in Patient-Derived Specimens Dana-Farber Cancer Institute Hahn, William C
Defining Neoantigen Immunodominance for Antigen Selection and Biomarker Discovery in Human Pancreatic Cancer Immunotherapy Sloan-Kettering Institute for Cancer Research Balachandran, Vinod P; Leach, Steven D 
Disrupting the Immune and Drug-Privileged Microenvironment in Pancreas Cancer Fred Hutchinson Cancer Research Center Hingorani, Sunil R 
Reprogramming Pdac Tumor Microenvironment to Improve Immunotherapy Massachusetts General Hospital Jain, Rakesh K; Pittet, Mikael
Resource Center for the Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies (U24) Pancreatic Ductal Adenocarcinoma Translational Resource Center (Patrec) University of Texas MD Anderson Cancer Center Wistuba, Ignacio I; Maitra, Anirban
Metabolic Reprogramming to Improve Immunotherapy (R01) Directing the Metabolic Fate of CAR T Cells University of Pennsylvania June, Carl H
Metabolic Reprogramming of Tregs in Tumor Immunity St. Jude Children’s Research Hospital Chi, Hongbo
  • Posted: October 22, 2018

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Create an Adult Immunotherapy Network was originally published by the National Cancer Institute.”

We welcome your comments on this post. All comments must follow our comment policy.